Drug makers must reveal payments to patient groups—closing a transparency gap

What it does

This bill requires pharmaceutical and device manufacturers to publicly disclose all payments and donations they make to patient advocacy organizations, starting March 31, 2027, and annually thereafter. The disclosure must include the organization's name and payment amount, and covers both direct payments and indirect payments routed through third parties. This expands an existing federal transparency requirement (the Open Payments program) that already covers payments to doctors and hospitals.

Why we flagged it

The bill's sole operative mechanism is to expand an existing public-disclosure regime (Open Payments) to cover a previously opaque category of payments. It does not restrict payments, impose penalties, or create new substantive rules—only visibility.

What the text implies

• Disclosure begins in 2027, giving manufacturers 18+ months to adjust relationships or restructure payments through less transparent channels before reporting begins.
• The definition of 'indirect payment' requires that the manufacturer 'requires, instructs, directs, or otherwise causes' the third party to pay the advocacy group—sophisticated payment structures designed to obscure the manufacturer's role may fall outside this definition.
• Patient advocacy organizations may face pressure to disclose their funding sources to members and the public, potentially reducing their perceived independence even if the funding is legitimate.
• Exemption from Paperwork Reduction Act (44 U.S.C. § 3501 et seq.) means the Secretary can impose reporting requirements without OMB review of burden, potentially creating compliance costs for manufacturers without public scrutiny of those costs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and patients gain transparency into financial relationships between manufacturers and advocacy groups that influence patient information and policy positions. Knowing which patient organizations receive manufacturer funding helps citizens evaluate the independence and potential bias of those groups when they advocate for drugs, devices, or policies.

Named in the bill

Pharmaceutical manufacturers, Device manufacturers, Group purchasing organizations (GPOs), Patient advocacy organizations (501(c)(3) nonprofits), Department of Health and Human Services (Secretary), Internal Revenue Service

Where it stands

1 cosponsor: 1 Democrats.

• Sep 4, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 4, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $8,410,000 in lobbying spend. A filing names 53 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Chuck Grassley, the sponsor, reported $49,167 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $8,410,000 on 1 filing

Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.